Drug Profile
Research programme: cathepsin C inhibitors - Merck Canada
Alternative Names: Dipeptidyl-peptidase 1 (DDP-1) inhibitors - Merck CanadaLatest Information Update: 25 Oct 2018
Price :
$50
*
At a glance
- Originator Merck Frosst
- Class
- Mechanism of Action Dipeptidyl peptidase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Cystic fibrosis
Most Recent Events
- 19 Sep 2007 Preclinical trials in Asthma in Canada (unspecified route)
- 19 Sep 2007 Preclinical trials in Cystic fibrosis in Canada (unspecified route)